Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021
Details related to Denalis oral presentation at MPS 2021 and a webinar hosted by Denali management following the presentation are provided below.
- Details related to Denalis oral presentation at MPS 2021 and a webinar hosted by Denali management following the presentation are provided below.
- Following the presentation, Denali will host a webinar for analysts and investors to present the interim data from the Phase 1/2 study of DNL310.
- Families interested in learning more about Denalis efforts related to the discovery and development of therapeutics for the potential treatment of Hunter syndrome are invited to visit EngageHunter.com , the Denali Hunter syndrome community engagement website.
- EngageHunter.com the Denali Hunter syndrome (MPS II) community engagement website is an online destination for emerging information on Denalis scientific advances in Hunter syndrome research and Denalis clinical trials.